Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Therapeutics

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CLINTHERA.2006.05.016PMID 16861093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fentanyl effervescent buccal tablets

  2006cited by this paper
• Consensus panel recommendations for the assessment and management of breakthrough pain parr I assessment

  2005cited by this paper
• Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers

  2005cited by this paper
• Confidence Interval Criteria for Assessment of Dose Proportionality

  2004cited by this paper
• Mechanistic Studies on Effervescent-Induced Permeability Enhancement

  1998cited by this paper
• The influence of in-vivo carbonation on GI physiological processes and drug permeability☆

  1997cited by this paper
• An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain.

  1991cited by this paper
• 1983 metropolitan height and weight tables.

  1983cited by this paper

• Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling

  2019influential citation
• Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis

  2017cites this paper
• Solid effervescent formulations as new approach for topical minoxidil delivery

  2017cites this paper
• Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.

  2017cites this paper
• Controlled release effervescent buccal discs of buspirone hydrochloride: in vitro and in vivo evaluation studies

  2016cites this paper
• Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain

  2015influential citation
• Fentanyl buccal tablet versus oral oxycodone for Emergency Department treatment of musculoskeletal pain

  2015cites this paper
• Efectividad del tratamiento del dolor irruptivo oncológico con comprimido bucal de fentanilo (CBF). Revisión bibliográfica de su farmacocinética, seguridad y empleo en situaciones clínicas especiales

  2014cites this paper
• Drug Class Review

  2014cites this paper
• Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.

  2013cites this paper
• Considerations in selecting rapid-onset opioids for the management of breakthrough pain

  2013cites this paper
• Medications for Cancer Breakthrough Pain

  2013cites this paper
• A review of the pharmacokinetic profile of transmucosal fentanyl formulations

  2012cites this paper
• Dose Proportionality of Fentanyl Buccal Tablet in Doses Ranging from 600 to 1300μg in Healthy Adult Subjects

  2012cites this paper
• Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain

  2012cites this paper
• A Review of Transbuccal Fentanyl Use in the Emergency Department

  2012cites this paper
• A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain

  2012cites this paper
• Rapid onset opioids in palliative medicine.

  2012cites this paper
• Fentanyl Buccal Tablet

  2012cites this paper
• Pharmacokinetics of Fentanyl Buccal Tablet: A Pooled Analysis and Review

  2012cites this paper
• Formulations of Fentanyl for the Management of Pain

  2012cites this paper
• Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids.

  2012cites this paper
• Pharmacokinetics of Non-Intravenous Formulations of Fentanyl

  2012cites this paper
• Fentanyl for breakthrough pain: a systematic review

  2011cites this paper
• Fentanyl nasal spray for the treatment of cancer pain

  2011cites this paper
• Tumordurchbruchschmerz

  2011cites this paper
• Breakthrough pain : Focus on Fentanyl Buccal Tablet

  2010cites this paper
• Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain: Pharmacokinetics of Buccal Mucosa Delivery and Clinical Efficacy

  2010cites this paper
• Recent development in therapeutics for breakthrough pain

  2010cites this paper
• Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications

  2010cites this paper
• Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.

  2010cites this paper
• Systematic evaluation of dose proportionality studies in clinical pharmacokinetics.

  2010cites this paper
• [Intranasal delivery of systemic drugs: a new route for opioid drugs].

  2010cites this paper
• Transbuccal fentanyl for rapid relief of orthopedic pain in the ED.

  2010cites this paper
• Combination Therapy with Budesonide and Formoterol in Single Inhaler of Asthma

  2009cites this paper
• Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion

  2009influential citation
• Novel formulations and routes of administration for opioids in the treatment of breakthrough pain

  2009cites this paper
• Critical evaluation of permeation enhancers for oral mucosal drug delivery.

  2009cites this paper
• Fentanyl buccal tablet.

  2008cites this paper
• Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers

  2008cites this paper
• Current Developments in Opioid Therapy for Management of Cancer Pain

  2008cites this paper
• Bioequivalence Following Buccal and Sublingual Placement of Fentanyl Buccal Tablet 400 μg in Healthy Subjects

  2008cites this paper
• Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 µg in Healthy Japanese Volunteers

  2008cites this paper
• Clinical pharmacology of fentanyl buccal tablet for the treatment of breakthrough pain

  2008cites this paper
• Dose Proportionality of Fentanyl Buccal Tablet in Healthy Japanese Volunteers

  2008cites this paper
• Formulation of Specialty Tablets for Slow Oral Dissolution

  2008cites this paper
• Current developments in opioid therapy for management of cancer pain.

  2008cites this paper
• A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet

  2008cites this paper
• Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet

  2007cites this paper
• Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain?

  2007influential citation
• Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study*

  2007cites this paper
• Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate

  2007cites this paper
• The treatment of breakthrough pain.

  2007cites this paper
• Fentanyl Effervescent Buccal Tablet

  2007influential citation
• Clinical use of opioids for cancer pain

  2007cites this paper
• Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.

  2007cites this paper